Pay in 4 interest-free payments of $47.50 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
Motesanib in combination with radiation displays significant anti-tumor activity in head and neck squamous cell carcinoma (HNSCC) xenograft models
CPT 11 hydrochloride
NSC 296962
is a potent and full thyroid stimulating hormone receptor (TSHR) agonist
selective and ATP-competitive Raf kinase inhibitor (IC50 = 10 nM)
NG25 Size:Solid 10 mg Motesanib in combination with radiationNG 25 is a type II kinase inhibitor that inhibits MAP4K2 and TAK1. It also inhibits the Src family kinases Src and LYN and Abl family kinases as well as CSK, FER, and p38. NG 25 prevents TNF induced IKK phosphorylation and IB degradation in L929 cells. It inhibits secretion of IFN and IFN induced by CpG type B and CL097, respectively. NG 25 decreases cell viability of HCT116KRASWT, and to a greater degree of HCT116KRASG13D, colorectal cancer cells in